The placebo response in the treatment of chronic fatigue syndrome: A systematic review and meta-analysis

Psychosomatic Medicine

Volumn 67, Issue 2, 2005, Pages 301-313

  Cho, Hyong Jin ^a   Hotopf, Matthew ^a   Wessely, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic fatigue syndrome; Expectation; Meta analysis; Meta regression; Placebo response; Systematic review

Indexed keywords

ACICLOVIR; ALBUMIN; ESSENTIAL FATTY ACID; FLUDROCORTISONE; FLUOXETINE; GALANTAMINE; HYDROCORTISONE; IMMUNOGLOBULIN; LINOLEIC ACID; MAGNESIUM; MALTOSE; MOCLOBEMIDE; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; STAPHYLOCOCCUS TOXOID; WATER;

BEHAVIOR THERAPY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITIVE THERAPY; CONFIDENCE INTERVAL; DEPRESSION; EMBASE; EPSTEIN BARR VIRUS; EXPECTATION; FIBROMYALGIA; HOMEOPATHY; HUMAN; KINESIOTHERAPY; MEDLINE; META ANALYSIS; MONONUCLEOSIS; NEURASTHENIA; PRIORITY JOURNAL; PSYCHOTHERAPY; PSYCINFO; REGRESSION ANALYSIS; RELAXATION TRAINING; REVIEW; SUPPORT GROUP; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 15744399820     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.psy.0000156969.76986.e0     Document Type: Review

References (110)

1. Shapiro AK. A historic and heuristic definition of the placebo. Psychiatry 1964;27:52-8.
2. Wolf S. The pharmacology of placebos. Pharmacol Rev 1959;11:689-704.
3. Beecher HK. The powerful placebo. JAMA 1955;159:1602-6.
4. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-7.
5. de Craen AJ, Moerman DE, Heisterkamp SH, Tytgat GN, Tijssen JG, Kleijnen J. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol 1999;48:853-60.
6. de Craen AJ, Tijssen JG, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 2000;247:183-8.
7. Pace F, Maconi G, Molteni P, Minguzzi M, Bianchi Porro G. Meta-analysis of the effect of placebo on the outcome of medically treated reflux esophagitis. Scand J Gastroenterol 1995;30:101-5.
8. Papakostas YG, Daras MD. Placebos, placebo effect, and the response to the healing situation: the evolution of a concept. Epilepsia 2001;42:1614-25.
9. Ader R. The role of conditioning in pharmacotherapy. In: Harrington A, editor. The placebo effect: an interdisciplinary exploration. Boston, London: Harvard University Press; 1997.
10. Voudouris NJ, Peck CL, Coleman G. Conditioned response models of placebo phenomena: further support. Pain 1989;38:109-16.
11. Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain 1990;43:121-8.
12. Montgomery GH, Kirsch I. Classical conditioning and the placebo effect. Pain 1997;72:107-13.
13. Price D, Fields H. The contribution of desire and expectation to placebo analgesia: implications for new research strategies. In: Harrington A, editor. The placebo effect: an interdisciplinary exploration. Boston, London: Harvard University Press; 1997.
14. Kirsch I. Specifying nonspecifics: psychological mechanisms of placebo effects. In: Harrington A, editor. The placebo effect: an interdisciplinary exploration. Boston, London: Harvard University Press; 1997.
15. Morris D. Placebo, pain, and belief: a biocultural model. In: Harrington A, editor. The placebo effect: an interdisciplinary exploration. Boston, London: Harvard University Press; 1997.
16. Lotshaw SC, Bradley JR, Brooks LR. Illustrating caffeine's pharmacological and expectancy effects utilizing a balanced placebo design. J Drug Educ 1996;26:13-24.
17. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7.
18. Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H. The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. Health Technol Assess 1999;3:1-96.
19. de la Fuente-Fernandez R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-6.
20. Reid S, Chalder T, Cleare A, Hotopf M, Wessely S. Chronic fatigue syndrome. BMJ 2000;320:292-6.
21. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med 2002;136:817-25.
22. Oh VM. The placebo effect: can we use it better? BMJ 1994;309:69-70.
23. Working Group Convened by the Royal Australasian College of Physicians. Draft Clinical Practice Guidelines on the evaluation of prolonged fatigue and the diagnosis and management of chronic fatigue syndrome. Med J Australia 2002. Available at: http://www.mja.com.au/public/guides/cfs/cfs1.html. Accessed August 15, 2002.
24. Hayden SP. A practical approach to chronic fatigue syndrome. Cleve Clin J Med 1991;58:116-20.
25. Wilson A, Hickie I, Lloyd A, Wakefield D. The treatment of chronic fatigue syndrome: science and speculation. Am J Med 1994;96:544-50.
26. Euba R, Chalder T, Deale A, Wessely S. A comparison of the characteristics of chronic fatigue syndrome in primary and tertiary care. Br J Psychiatry 1996;168:121-6.
27. Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001;286:1360-8.
28. Lloyd AR, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, Wakefield D. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203.
29. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4. 2nd ed. March 2001. Available at: http://www.york.ac.uk/inst/crd/report4.htm. Accessed August 1, 2002.
30. StataCorp: Stata Statistical Software. College Station, TX: Stata Corp; 2002.
31. Davey Smith G, Egger M, Phillips NA. Meta-analysis. beyond the grand mean? BMJ 1997;315:1610-4.
32. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-5.
33. Deale A, Husain K, Chalder T, Wessely S. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. Am J Psychiatry 2001;158:2038-42.
34. Hickie IB, Wilson AJ, Wright JM, Bennett BK, Wakefield D, Lloyd AR. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry 2000;61:643-8.
35. Powell P, Bentall RP, Nye FJ, Edwards RH. Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome. BMJ 2001;322:387-90.
36. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, van der Wilt GJ, Spinhoven P, van der Meer JW. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001;357:841-7.
37. Ridsdale L, Godfrey E, Chalder T, Seed P, King M, Wallace P, Wessely S. Chronic fatigue in general practice: is counselling as good as cognitive behaviour therapy? a UK randomised trial. Br J Gen Pract 2001;51:19-24.
38. Rowe PC, Calkins H, DeBusk K, McKenzie R, Anand R, Sharma G, Cuccherini BA, Soto N, Hohman P, Snader S, Lucas KE, Wolff M, Straus SE. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA 2001;285:52-9.
39. Brostoff J. A phase II, randomised, placebo controlled study to assess the safety and efficacy of anti cholineskinase drugs in patients with a diagnosis of chronic fatigue syndrome. National Research Register, 2000.
40. Burgess M, Chalder T. Telephone cognitive behaviour therapy for chronic fatigue syndrome in secondary care: a case series. Behav Cog Psychoth 2001;29.
41. Chisholm D, Godfrey E, Ridsdale L, Chalder T, King M, Seed P, Wallace P, Wessely S. Chronic fatigue in general practice: economic evaluation of counselling versus cognitive behaviour therapy. Br J Gen Pract 2001;51:15-8.
42. Cleare AJ, O'Keane V, Miell J. Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion. Clin Endocrinol (Oxf) 2001;55:113-9.
43. Garralda E. Family-focused cognitive behavioural family therapy for adolescents with chronic fatigue syndrome. National Research Register, 2001.
44. Klimas NG, Patarca Montero R, Maher K, Smith M, Bathe O, Fletcher MA. Clinical and immunologic effects of autologous lymph node cell transplant in chronic fatigue syndrome. J Chronic Fatigue Syndrome 2001;8:39-55.
45. Kurek JN. Treatment of chronic fatigue syndrome with methylphenidate. Tulsa: University of Tulsa; 2001.
46. Lerner AM, Zervos M, Chang CH, Beqaj S, Goldstein J, O'Neill W, Dworkin H, Fitgerald T, Deeter RG. A small, randomized, placebo-controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. Clin Infect Dis 2001;32:1657-8.
47. McKenzie R, Reynolds JC, O'Fallon A, Dale J, Deloria M, Blackwelder W, Straus SE. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol 2000;27:2222-6.
48. Mitchell AJ. A phase II randomised, placebo-controlled study to assess the safety and efficacy of galantamine hydrobromide 25mg TID, 5mg TID, 75mg TID and 10mg TID taken for a period of 16 weeks in patients with a diagnosis of chronic fatigue syndrome (CFS). National Research Register, 2000.
49. Ockerman PA. Antioxidant treatment of chronic fatigue syndrome. Clin Pract Alternat Med 2000;1:88-91.
50. Regland B, Zachrisson O, Stejskal V, Gottfries CG. Nickel allergy is found in a majority of women with chronic fatigue syndrome and muscle pain and may be triggered by cigarette smoke and dietary nickel intake. J Chronic Fatigue Syndrome 2001;8:57-65.
51. Sadlier M, Evans JR, Phillips C, Broad A. A preliminary study into the effectiveness of multi-convergent therapy in the treatment of heterogeneous patients with chronic fatigue syndrome. J Chronic Fatigue Syndrome 2000;7:93-101.
52. Sleigh KM, Danforth DG, Hall RT, Fleming JA, Stiver HG. Double-blind, randomized study of the effects of influenza vaccination on the specific antibody response and clinical course of patients with chronic fatigue syndrome. Can J Infect Dis 2000;11:267-73.
53. Soderberg S, Evengard B. Short-term group therapy for patients with chronic fatigue syndrome. Psychother Psychosom 2001;70:108-11.
54. Spath M, Welzel D, Farber L. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists: preliminary results. Scand J Rheumatol 2000;(suppl):11372-7.
55. Stanley PJ: Chronic fatigue syndrome: a controlled trial of the efficacy of homeopathic treatment. National Research Register, 2001.
56. Teitelbaum JE, Bird B, Weiss A, Gould L. Low-dose hydrocortisone for chronic fatigue syndrome. J Chronic Fatigue Syndrome 1999;281:1887-8.
57. Waldman PN. Vitamin therapy in the treatment of depression associated with chronic fatigue syndrome. Wladen University; 2001.
58. Wessely S. A randomised controlled trial of cognitive behaviour therapy for chronic fatigue syndrome. National Research Register, 2000.
59. White PD, Naish VAB. Graded exercise therapy for chronic fatigue syndrome. Physiotherapy 2001;87:285-8.
60. White PD, Naish VAB. Graded movement therapy for chronic fatigue syndrome. Physiotherapy 2001;87:614-6.
61. Blacker CV, Greenwood DT, Wesnes KA, Wilson R, Woodward C, Howe I, AH T. Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. JAMA 2004;292:1195-204.
62. Brouwers FM, van der Werf S, Bleijenberg G, van der Zee L, van der Meer JWM. The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: a double-blind randomized controlled trial. Q J Med 2002;95:677-83.
63. Candy B, Chalder T, Cleare AJ, Wessely S, Hotopf M. A randomised controlled trial of a psycho-educational intervention to aid recovery in infectious mononucleosis. J Psychosom Res 2004;57:89-94.
64. Weatherley-Jones E, Nicholl JP, Thomas KJ, Parry GJ, McKendrick MW, Green ST, Stanley PJ, Lynch SP. A randomised, controlled, triple-blind trial of the efficacy of homeopathic treatment for chronic fatigue syndrome. J Psychosom Res 2004;56:189-97.
65. Zachrisson O, Regland B, Jahreskog M, Jonsson M, Kron M, Gottfries CG. Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome: a randomised controlled trial. Eur J Pain 2002;6:455-66.
66. Andersson M, Bagby JR, Dyrehag LE, Gottfries CG. Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. Eur J Pain 1998;2:133-42.
67. Awdry R. Homeopathy may help ME. Int J Altern Complement Med 1996;14:12-6.
68. Behan PO, Behan WM, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990;82:209-16.
69. Brook MG, Bannister BA, Weir WR. Interferon-alpha therapy for patients with chronic fatigue syndrome. J Infect Dis 1993;168:791-2.
70. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised cross-over trial. Lancet 1999;353:455-8.
71. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991;337:757-60.
72. Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry 1997;154:408-14.
73. DuBois R. Gamma globulin therapy for chronic mononucleosis syndrome. AIDS Res 1986;2:S191-5.
74. Field TM, Sunshine W, Hernandez Reif M, Quintino O, Schanberg S, Kuhn C, Burman I. Massage therapy effects on depression and somatic symptoms in chronic fatigue syndrome. J Chronic Fatigue Syndrome 1997;3:43-51.
75. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999;82:185-91.
76. Friedberg F, Krupp LB. A comparison of cognitive behavioral treatment for chronic fatigue syndrome and primary depression. Clin Infect Dis 1994;18(suppl 1):S105-10.
77. Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. BMJ 1997;314:1647-52.
78. Goudsmit E. Learning to cope with post-infectious fatigue syndrome: a follow-up study in the psychological aspects and management of chronic fatigue syndrome [dissertation]. Uxbridge, England: Brunel University; 1996.
79. Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. Arch Intern Med 1989;149:2501-3.
80. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990;89:561-8.
81. Marlin RG, Anchel H, Gibson JC, Goldberg WM, Swinton M. An evaluation of multidisciplinary intervention for chronic fatigue syndrome with long-term follow-up, and a comparison with untreated controls. Am J Med 1998;105:110s-4s.
82. Martin RWY, Ogston SA, Evans JR. Effects of vitamin and mineral supplementation on symptoms associated with chronic fatigue syndrome with Coxsackie B antibodies. J Nutr Med 1994;4:11-23.
83. McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, Garcia Borreguero D, Blackwelder W, Straus SE. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998;280:1061-6.
84. Moorkens G, Wynants H, Abs R. Effect of growth hormone treatment in patients with chronic fatigue syndrome: a preliminary study. Growth Horm IGF Res 1998;8:B131-3.
85. Natelson BH, Cheu J, Hill N, Bergen M, Korn L, Denny T, Dahl K. Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology 1998;37:150-4.
86. Natelson BH, Cheu J, Pareja J, Ellis P, Policastro T, Findley TW. Randomized, double blind, controlled placebo phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology 1996;124:226-30.
87. Perrin RN, Edwards J, Hartley P. An evaluation of the effectiveness of osteopathic treatment on symptoms associated with myalgic encephalomyelitis: a preliminary report. J Med Eng Technol 1998;22:1-13.
88. Peterson PK, Pheley A, Schroeppel J, Schenck C, Marshall P, Kind A, Haugland JM, Lambrecht LJ, Swan S, Goldsmith S. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998;158:908-14.
89. Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, Lurie N. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990;89:554-60.
90. Rowe KS. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. J Psychiatr Res 1997;31:133-47.
91. Schlaes J, Jason LA. A buddy/mentor program for PWCs. CFIDS Chron 1996:21-5.
92. See DM, Tilles JG. Alpha-interferon treatment of patients with chronic fatigue syndrome. Immunol Invest 1996;25:153-64.
93. Sharpe M, Hawton K, Simkin S, Surawy C, Hackmann A, Klimes I, Peto T, Warrell D, Seagroatt V. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial. BMJ 1996;312:22-6.
94. Snorrason E, Geirsson A, Stefansson K. Trial of a selective acetylcholinesterase inhibitor, galanthamine hydrobromide, in the treatment of chronic fatigue syndrome. J Chronic Fatigue Syndrome 1996;2:35-54.
95. Steinberg P, McNutt BE, Marshall P, Schenck C, Lurie N, Pheley A, Peterson PK. Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. J Allergy Clin Immunol 1996;97:119-26.
96. Stewart W, Rowse C: Supplements help ME says Kiwi study. J Altern Complement Med 1987;5:19-20, 22.
97. Straus SE, Dale JK, Tobi M, Lawley T, Preble O, Blaese RM, Hallahan C, Henle W. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial. N Engl J Med 1988;319:1692-8.
98. Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18:1s88-95.
99. Tiev KP, Cabane J, Imbert JC. Sulbutiamine treatment for chronic postinfectious fatigue (CPIF): a double-blind study [French]. Rev Med Interne 1999;20:912-8.
100. Vercoulen JH, Swanink CM, Zitman FG, Vreden SG, Hoofs MP, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996;347:858-61.
101. Vollmer Conna U, Hickie I, Hadzi Pavlovic D, Tymms K, Wakefield D, Dwyer J, Lloyd A. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997;103:38-43.
102. Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome: a case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA. Acta Neurol Scand 1999;99:112-6.
103. Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, Campbell IT, Morris JA. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 1998;172:485-90.
104. Cochrane reviewers' handbook. Available at: http://www.cochrane.dk/ cochrane/handbook/handbook.htm. Accessed January 24, 2003.
105. Bootzin RR, Caspi O. Explanatory mechanisms for placebo effects: cognition, personality and social learning. In: Guess HA, Kleinman A, Kusek JW, Engel LW, editors. The science of the placebo: toward an interdisciplinary research agenda. London: BMJ Books; 2002:108-32.
106. McDonald CJ, McCabe GP. How much of the placebo "effect" is really statistical regression? Stat Med 1989;8:1301-2.
107. Kienle GS, Kiene H. The powerful placebo effect: fact or fiction? J Clin Epidemiol 1997;50:1311-8.
108. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? an analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602.
109. Gill D, Hatcher S. Antidepressants for depression in medical illness [update of Cochrane Database Syst Rev 2000;(2):CD001312]. Cochrane Database Syst Rev 2000;CD001312.
110. Gill D, Hatcher S. Antidepressants for depression in medical illness [update of Cochrane Database Syst Rev 2000;(2):CD001312]. Cochrane Database Syst Rev 2000;CD001312.